Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application

Journal of Radioanalytical and Nuclear Chemistry

Volumn 299, Issue 3, 2014, Pages 1389-1398

  Das, Tapas ^a   Bhadwal, Mohini ^a   Banerjee, Sharmila ^a   Sarma, H D ^a   Shinto, Ajit ^b   Kamaleshwaran, K K ^b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b KOVAI MEDICAL CENTER AND HOSPITAL   (India)

Author keywords

Freeze dried DOTA NOC kit; Freeze dried DOTA TATE kit; Neuroendocrine cancers; PRRNT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 SODIUM IODIDE] LY 177; AMMONIUM ACETATE; GENTISIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PURITY; DRUG RETENTION; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; FREEZE DRYING; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; NEUROENDOCRINE TUMOR; NONHUMAN; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; QUALITY CONTROL; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING;

EID: 84894771906     PISSN: 02365731     EISSN: 15882780     Source Type: Journal    
DOI: 10.1007/s10967-013-2894-z     Document Type: Article

References (26)

1. Pool SE, Krenning EP, Koning GA, van Eijck CHJ, Teunissen JJM, Kam B, Valkema R, Kwekkeboom DJ, de Jong M (2010) Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 40:209-218
2. Kwekkeboom DJ, de Herder WW, van Eijck CHJ, Kam BL, van Essen M, Teunissen JJM, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40:78-88
3. Ansquer C, Kraeber-Bodéré F, Chatal JF (2009) Current status and perspectives in peptide receptor radiation therapy. Curr Pharma Des 15:2453-2462
4. van Essen M, Krenning EP, Kam BLR, De Jong M, Valkema R, Kwekkeboom DJ (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5:382-393
5. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 32:360-369
6. Baum RP (2013) Peptide receptor radionuclide therapy of neuroendocrine tumors: experience in over 1100 patients and long term results. World J Nucl Med 12(suppl 1):111-113
7. 177Lu-DOTA-TATE therapy in patients with disseminated NET. Radiother Oncol 102:45-50
8. 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93:189-196
9. 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 51:1524-1531
10. 177Lu-DOTATOC. Recent Results Can Res 194:519-536
11. Esser JP, Krenning EP, Teunissen JJM, Kooij PPM, van Gameran ALH, Bakker WH, Kwekkeboom DJ (2006) Comparison of [177Lu-DOTA0, Tyr3]octreotate and [177Lu-DOTA0, Tyr3]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33:1346-1351
12. 177Lu-DOTA-NOC. Cancer Biother Radiopharm 22:406-416
13. 177Lu-DOTA-TATE. Cancer Biother Radiopharm 27:593-599
14. 177Lu-DOTA-TATE. Clin Nucl Med 38:188-194
15. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, de Jong M, Wenger S, Reubi JC (2003) DOTA-NOC, a high affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338-1347
16. 5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502-511
17. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30:917-920
18. Das T, Pillai MRA (2013) Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 40:23-32
19. 177Lu in medium flux reactor. Appl Radiat Isot 65:301-308
20. 177Lu: the Indian experience. Cancer Biother Radiopharm 26:395-400
21. 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38:1788-1797
22. Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319-1325
23. Das T, Chakraborty S, Banerjee S, Venkatesh M (2012) Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. Radiochim Acta 100:115-126
24. 177Lu for radionuclide therapy. Appl Radiat Isot 59:109-118
25. Awasthi V, Meinken G, Springer K, Srivastava SC, Freimuth P (2004) Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J Virol 78:6431-6438
26. 2 for bone pain palliation. Nucl Med Biol 36:561-568